X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory mNPM1 Acute Myeloid Leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
INCA034176 (axatilimab) is an investigational monoclonal antibody that targets CSF-1R. It is bein evaluated for the treatment of chronic graft-versus-host disease.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Product Name: INCA034176
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
The net proceeds will be used for the ongoing and expanded clinical development of SNDX-6352 (axatilimab) and revumenib, expenses related to the potential U.S. commercial launch of axatilimab in patients with cGVHD and revumenib in defined subsets of acute leukemias patients.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Product Name: SNDX-6352
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2023
Details:
The net proceeds will fund the ongoing and expanded clinical development of axatilimab and revumenib and expenses related to the potential U.S. commercial launch of axatilimab in patients with cGVHD and revumenib in defined subsets of acute leukemias patients.
Lead Product(s): Axatilimab
Therapeutic Area: Immunology Product Name: SNDX-6352
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 14, 2023
Details:
SNDX-5613 (revumenib) is a highly selective, oral menin inhibitor which is under phase 1 clinical development for the treatment of patients with Acute Leukemias.
Lead Product(s): Revumenib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged, also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including ALL and AML, and NPM1-mutant AML.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of R/R KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor, which is investigated for the treatment of relapsed/refractory KMT2Ar acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
SNDX-5613 (revumenib) is an investigational, novel, orally available Menin-MLL1 inhibitor. The interaction of Menin and MLL1 has been demonstrated to play an essential role in the leukemic transformation for acute leukemia patients with MLLr or NPM1 mutation.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Product Name: SNDX-5613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
